NASDAQ:BRBI BR Biopharma (BRBI) Stock Price, News & Analysis $7.40 -0.22 (-2.89%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$7.42 +0.02 (+0.27%) As of 11/20/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsOwnershipSEC FilingsShort Interest About BR Biopharma Stock (NASDAQ:BRBI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BR Biopharma alerts:Sign Up Key Stats Today's Range$6.85▼$8.2950-Day Range$6.80▼$15.3652-Week Range$6.80▼$16.61Volume28,765 shsAverage Volume9,484 shsMarket Capitalization$87.39 millionP/E Ratio52.86Dividend Yield4.32%Price TargetN/AConsensus RatingReduce Company Overview Brii Biosciences Limited is a biotechnology company focused on developing treatments for infectious diseases and other conditions with significant unmet medical needs. Founded in 2017, the company has operated in the United States and China. Its research has included investigational therapies for chronic hepatitis B and other viral diseases, as well as drug-resistant bacterial infections. The company’s development programs have included BRII-179, a therapeutic vaccine candidate for hepatitis B, and BRII-835, an investigational RNA-based therapy. These candidates are not described here as approved or marketed medicines.AI Generated. May Contain Errors. Read More BR Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreBRBI MarketRank™: 0.772312016865 of 5 starsBR Biopharma scored higher than 15% of companies evaluated by MarketBeat, and ranked 762nd out of 813 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingBR Biopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageBR Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about BR Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BR Biopharma is 52.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.17.Price to Earnings Ratio vs. SectorThe P/E ratio of BR Biopharma is 52.86, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 19.44.Price to Book Value per Share RatioBR Biopharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of BR Biopharma has been sold short.Short Interest Ratio / Days to CoverBR Biopharma has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BR Biopharma has recently increased by 1,264.34%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipBR Biopharma is a leading dividend payer. It pays a dividend yield of 4.27%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBR Biopharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BR Biopharma is 228.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BR Biopharma's dividend. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for BR Biopharma this week, compared to 1 article on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BR Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders29.35% of the stock of BR Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBR Biopharma has minimal institutional ownership at this time.Read more about BR Biopharma's insider trading history. Receive BRBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BR Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRBI Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com BRBI Stock Analysis - Frequently Asked Questions How have BRBI shares performed this year? BR Biopharma's stock was trading at $14.75 on February 17, 2026. Since then, BRBI shares have decreased by 49.8% and is now trading at $7.40. How were BR Biopharma's earnings last quarter? BR Biopharma, Inc. (NASDAQ:BRBI) posted its quarterly earnings data on Tuesday, November, 3rd. The company reported $0.05 earnings per share (EPS) for the quarter. The firm earned $23.80 million during the quarter. Read the conference call transcript. How do I buy shares of BR Biopharma? Shares of BRBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 9/4 Dividend8/17/2026Ex-Dividend for 9/4 Dividend8/17/2026Dividend Payable9/04/2026Last Earnings11/03/2026Record date for 12/4 Dividend11/16/2026Ex-Dividend for 12/4 Dividend11/16/2026Today11/22/2026Dividend Payable12/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Capital Markets Sub-IndustryInvestment Banking & Brokerage Current SymbolNASDAQ:BRBI CIK2058601 Webwww.brpartners.com.br Phone55-11-3704-1000FaxN/AEmployees189Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio52.86 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$2.23 billion Price / Sales0.04 Cash Flow$2.82 per share Price / Cash Flow2.62 Book Value$13.70 per share Price / Book0.54Miscellaneous Outstanding Shares11,810,000Free Float8,344,000Market Cap$87.39 million OptionableN/A Beta0.43 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:BRBI) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BR Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BR Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.